Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients

Iizuka, Yoichi; Iizuka, Haku; Kaneko, Tetsuya; Mieda, Tokue; Takechi, Rumi; Suzuki, Hitoshi; Sorimachi, Yasunori; Suto, Takeshi; Tachibana, Makiko; Yoneyama, Tomotaka; Omodaka, Takuya; Hashimoto, Shogo; Hamano, Noritaka; Sakane, Hideo; Shimoyama, Daisuke; Kohama, Isaku; Ohshima, Atsufumi; Nozaki, Tatsuya; Kamiyama, Masataka; Moteki, Tomohiko; Ohshima, Asuka; Takamine, Shuhei; Honda, Akira; Ueno, Akira; Tajika, Tsuyoshi; Okamura, Keisuke; Warita, Toshiro; Yonemoto, Yukio; Shitara, Hitoshi; Ohsawa, Takashi; Takagishi, Kenji

doi:10.1016/j.injury.2016.09.031

Cited by 10 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They suggested that severe suppression of bone turnover was associated with the pathogenesis of AFF. [65] Systematic review of case report and case series on AFF presented that bone formation marker was decreased in 14%, normal in 79%, and increased in 7.0% in AFF patients. And bone resorption marker was decreased 18.2%, normal 69.7%, and increased 12.1% in AFF patients.…”

Section: Clinical Utility Of Btmsmentioning

confidence: 99%

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

et al. 2019

View full text Add to dashboard Cite

Current evidences continue to support the clinical application of bone turnover markers (BTMs) in the management of postmenopausal osteoporosis. The limitations of bone mineral density measured by dual energy X-ray absorptiomet especially emphasize the beneficial roles of BTMs, such as serum C-terminal telopeptide of type I collagen and serum procollagen type I N-propeptide, as monitoring tools to assess the responses to treatment. Therefore, the proper application and assessment of BTM in clinical practice is very important. However, their use in Korea is still insufficient. Therefore, the BTM committee has set up by the Korean Society for Bone and Mineral Research have been constituted and provided a position statement which will suggest on the clinical application of BTM for the management of postmenopausal osteoporosis in Korea.

show abstract

Section: Clinical Utility Of Btmsmentioning

confidence: 99%

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Monitoring bone turnover markers during a drug holiday could potentially help in deciding when to resume treatment, but the evidence is not sufficient. Long-term use of bisphosphonates is associated with rare but serious side effects such as osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFF) [ 34 ]. Therefore, a “bisphosphonate drug holiday” concept has emerged as an alternative option that could circumvent such side effects.…”

Section: Diagnosis and Evaluation Of Osteoporosismentioning

confidence: 99%

“…In one prospective cross-sectional study, bone turnover marker test values, including P1NP, tartrate-resistant acid phosphatase 5b, and undercarboxylated OC, were significantly lower in patients with AFF patients than in patients with a typical osteoporotic femur fracture. They suggested that a severe suppression of bone turnover is associated with AFF [ 34 ].…”

Section: Diagnosis and Evaluation Of Osteoporosismentioning

confidence: 99%

The 2024 Guidelines for Osteoporosis - Korean Society of Menopause

Lee,

Hong,

Cho

et al. 2024

J Menopausal Med

View full text Add to dashboard Cite

“…7,13 A biomarker study found levels of bone turnover markers (including N-terminal propeptides of type 1 procollagen, isoform 5b of tartrate-resistant acid phosphatase, and undercarboxylated osteocalcin) to be significantly lower in patients with AFF compared to those with typical femoral fractures, supporting the hypothesis that severe suppression of bone turnover is involved the pathogenesis of AFF. 14…”

Section: Introductionmentioning

confidence: 99%

The limitations of today’s clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting

Cheung

Borno

2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

While bone-modifying agents such as bisphosphonates and denosumab are crucial to preventing skeletal-related events in patients with bone metastases, the optimal duration remains undefined. Extended duration may be associated with adverse effects such as osteonecrosis of the jaw and atypical femoral fracture. Although uncommon, atypical femoral fracture represents a serious consequence of prolonged bone-modifying agent use and are characterized by a prodrome and distinct radiographic findings. The oncology setting encompasses a unique set of atypical femoral fracture risk factors and considerations, with hormonal therapy in early stage disease, bone metastases in the advanced setting, and new targeted agents that may affect bone homeostasis. As outcomes in cancer treatment continue to improve, the questions of risks versus benefits of long-term bone-modifying agents and how to mitigate atypical femoral fracture risk become increasingly pertinent.

show abstract

Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients

Cited by 10 publications

References 31 publications

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

The 2024 Guidelines for Osteoporosis - Korean Society of Menopause

The limitations of today’s clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting

Contact Info

Product

Resources

About